A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study with an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects with Psoriatic Arthritis.
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2016
At a glance
- Drugs Brodalumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Amgen
- 28 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 14 Jun 2014 Results presented at the 15th Annual Congress of the European League Against Rheumatism.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History